Deposition of Inhaled Particles in the Lungs

Tena, Ana Fernández; Clarà, Pere Casan

doi:10.1016/j.arbr.2012.02.006

Cited by 141 publications

(52 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The emitted dose that is 16 swallowed, or inhaled into the lungs, reaches the systemic 17 circulation via the gastrointestinal and pulmonary routes, respec-18 tively. The drug particle size distribution, measured by in-vitro 19 methodologies, provides an appreciation of the amount of drug 20 that will impact onto the oropharyngeal region and the distribu- and its distribution is an indicator of lung deposition, hence a 28 marker for efficacy (Fernandez Tena and Casan Clara, 2012;Labiris 29 and Dolovich, 2003). 30 The dose, and its particle size distribution, emitted from a dry 31 powder inhaler (DPI), is determined by the inhalation manoeuvre 32 performed by the patient, the inhaler and the formulation.…”

Section: Introductionmentioning

confidence: 99%

Effect of inhalation profile and throat geometry on predicted lung deposition of budesonide and formoterol (BF) in COPD: An in-vitro comparison of Spiromax with Turbuhaler

Chrystyn¹,

Safioti²,

Keegstra

et al. 2015

International Journal of Pharmaceutics

View full text Add to dashboard Cite

Successful delivery of inhalation medication to the lungs can be affected by the inhalation manoeuvre used. Conventional in-vitro testing of the emitted dose from a dry powder inhaler (DPI) uses a vacuum pump to simulate an inhalation. We have adapted this method by replacing the pump with patient inhalation profiles and an anatomical throat. Three anatomical throat sizes and three inhalation profiles were used. The profiles represented the 10th, 50th and 90th percentiles of peak inhalation flow and acceleration of flow from a population of 50 COPD patients inhaling through empty Spiromax and Turbuhaler devices. Combining the dose emission results for the three throat sizes, the mean (SD) budesonide fine-particle dose (FPD) from budesonide-formoterol Spiromax 320/9 μg was 78.91 (20.18), 79.91 (15.36) and 75.10 (19.91)μg and the total emitted dose (TED) of budesonide was 263.69 (40.74), 261.20 (21.65) and 261.61 (45.65)μg. Similarly, the FPD from 320/9 μg Turbuhaler was 22.45 (3.24), 52.20 (12.57) and 69.11 (75.10)μg with a TED of 143.80 (14.90), 149.50 (26.61) and 158.61 (43.04)μg. Spiromax showed greater consistency than Turbuhaler over a range of inspiratory flow profiles. The results demonstrate the value of this new method to assess the doses that patients receive during real-life use of their DPI.

show abstract

Section: Introductionmentioning

confidence: 99%

Effect of inhalation profile and throat geometry on predicted lung deposition of budesonide and formoterol (BF) in COPD: An in-vitro comparison of Spiromax with Turbuhaler

Chrystyn¹,

Safioti²,

Keegstra

et al. 2015

International Journal of Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…Therefore, the mode of pulmonary delivery also plays a crucial role in facilitating NP deposition and distribution in distal lung tissue. Use of a metered dose inhaler or a dry powder inhaler could result in significant oropharyngeal NP deposition and variation in dosage when the device is not shaken correctly [18]. Use of a nebulizer on the other hand could maintain a relatively constant size of aerosol droplets in the range (4–6µm diameter) that easily allow the suspended NPs to reach the distal lung.…”

Section: Introductionmentioning

confidence: 99%

Polymeric nanoparticles for pulmonary protein and DNA delivery

et al. 2014

View full text Add to dashboard Cite

Polymeric nanoparticles (NPs) are promising carriers of biological agents to lung due to advantages including biocompatibility, ease of surface modification, localized action and reduced systemic toxicity. However, there have been no studies extensively characterizing and comparing the behavior of polymeric NPs for pulmonary protein/DNA delivery both in vitro and in vivo. We screened six polymeric NPs: gelatin, chitosan, alginate, poly lactic-co-glycolic acid (PLGA), PLGA-chitosan, and PLGA-polyethylene glycol (PEG), for inhalational protein/ DNA delivery. All NPs except PLGA-PEG and alginate were <300 nm in size with bi-phasic core compound release profile. Gelatin, PLGA NPs and PLGA-PEG NPs remained stable in deionized water, serum, saline and simulated lung fluid (Gamble’s solution) over 5 days. PLGA-based NPs and natural polymer NPs exhibited highest cytocompatibility and dose-dependent in vitro uptake respectively by human alveolar type-1 epithelial cells. Based on these profiles, gelatin and PLGA NPs were used to encapsulate a) plasmid DNA encoding yellow fluorescent protein (YFP) or b) rhodamine-conjugated erythropoietin (EPO) for inhalational delivery to rats. Following a single inhalation, widespread pulmonary EPO distribution persisted for up to 10 days while increasing YFP expression was observed for at least 7 days for both NPs. The overall results support both PLGA and gelatin NPs as promising carriers for pulmonary protein/DNA delivery.

show abstract

“…Inhaler technique requires a complex set of steps to be performed to enable drug delivery into the lungs and even with optimal technique typically <20% of the inhaled drug reaches the site of action 7. This figure is dramatically reduced when not administered correctly 7.…”

mentioning

confidence: 99%

“…This figure is dramatically reduced when not administered correctly 7. In addition, pharmaceutical companies commonly suggest different administration steps for similar devices; it is little wonder why there is confusion regarding inhaler technique among clinicians and patients alike.…”

mentioning

confidence: 99%

Do healthcare professionals understand asthma devices?: Table 1

Goodwin

Heraghty

2015

Arch Dis Child Educ Pract Ed

View full text Add to dashboard Cite

Asthma is a common, complex and multifactorial respiratory condition affecting a significant number of children within the UK. Recent department of health reports and national guidance has highlighted that healthcare professionals have a poor understanding of asthma treatments and are failing to provide patients with basic care. This article aims to explore some of the reasons why the use of inhalers is inadequate and discusses the research surrounding the reported knowledge of healthcare professionals' ability to counsel on inhaler devices. We hope the article will help clinicians explore their understanding of how to administer commonly prescribed inhaler devices, provide useful general and simple steps for inhaler counselling and act as a prompt to review personal competence and confidence in counselling on inhaler devices.

show abstract

Deposition of Inhaled Particles in the Lungs

Cited by 141 publications

References 47 publications

Effect of inhalation profile and throat geometry on predicted lung deposition of budesonide and formoterol (BF) in COPD: An in-vitro comparison of Spiromax with Turbuhaler

Effect of inhalation profile and throat geometry on predicted lung deposition of budesonide and formoterol (BF) in COPD: An in-vitro comparison of Spiromax with Turbuhaler

Polymeric nanoparticles for pulmonary protein and DNA delivery

Do healthcare professionals understand asthma devices?: Table 1

Contact Info

Product

Resources

About